W. Eiermann

ResearcherPublications, citations & collaboration network

W. Eiermann is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 450 works, 44,943 citations, an h-index of 69 and an i10-index of 149.

450

Works

44,943

Citations

h-index

149

i10-index

IDs:OpenAlex

How has W. Eiermann's publication output changed over time?

ScholarIQpublication output · 2001–2020

Output declined50% over the shown period — from 2 works in 2001 to 1 in 2020.

2001200520062010201120122013201420182020

What are the most-cited papers on W. Eiermann?

ScholarIQmost cited works

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton

New England Journal of Medicine. 200111,555 CitationsOPEN ACCESS

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz

The Lancet. 20144,765 CitationsOPEN ACCESS

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown

New England Journal of Medicine. 20112,784 CitationsOPEN ACCESS

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl

Journal of Clinical Oncology. 20122,692 Citations

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum

New England Journal of Medicine. 20182,178 CitationsOPEN ACCESS

Related on ScholarIQ

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Paper

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Paper

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Paper

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Paper

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Paper

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Paper